Company IXICO plc

Equities

IXI

GB00BFXR4C20

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for IXICO plc

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:09 2024-05-03 EDT			5-day change	1st Jan Change
8.125 ^GBX	0.00%		-5.80%	-35.00%

04-15	Ixico inks supply agreement with Life Molecular Imaging for Neuraceq	AN
04-15	IXICO plc Provides Information on Its Agreement with Life Molecular Imaging for the Supply of Neuraceq Amyloid PET Tracer	CI

IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.

Number of employees: 89

GBP in Million	2022	Weight	2023	Weight	Delta
Clinical Trials Services 100.0 %	9	100.0 %	7	100.0 %	-22.89%

GBP in Million	2022	Weight	2023	Weight	Delta
United States 45.8 %	3	31.4 %	3	45.8 %	+12.62%
United Kingdom 14.3 %	2	23.8 %	1	14.3 %	-53.72%
Netherlands 12.9 %	0	5.0 %	1	12.9 %	+97.71%
Switzerland 12.2 %	2	24.0 %	1	12.2 %	-60.71%
Ireland 10.3 %	1	8.4 %	1	10.3 %	-4.83%
Europe 4.4 %	1	7.4 %	0	4.4 %	-54.08%

Managers	Title	Age	Since
Giulio Cerroni CEO	Chief Executive Officer	63	17-02-05
Grant Robert Nash DFI	Director of Finance/CFO	47	19-05-30
Charles Spicer CHM	Chairman	59	13-10-13
Romina Oxborough COO	Chief Operating Officer	-	-
Robin Wolz CTO	Chief Tech/Sci/R&D Officer	-	20-12-31
Michelle Lax CTO	Chief Tech/Sci/R&D Officer	45	11-12-31

Members of the board	Title	Age	Since
Charles Spicer CHM	Chairman	59	13-10-13
Mark Robert Warne BRD	Director/Board Member	49	16-09-15
Dipti Amin BRD	Director/Board Member	60	23-10-04
Giulio Cerroni CEO	Chief Executive Officer	63	17-02-05
Grant Robert Nash DFI	Director of Finance/CFO	47	19-05-30
Katherine Jane Rogers BRD	Director/Board Member	57	22-01-20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	48,351,373	24,741,986 ( 51.17 %)	0	51.17 %

Name	Equities	%	Valuation
BGF Investment Management Ltd. 18.46 %	8,924,000	18.46 %	913 104 p
Octopus Investments Ltd. 13.25 %	6,408,400	13.25 %	655 707 p
Gresham House Asset Management Ltd. 10.69 %	5,166,972	10.69 %	528 685 p
Canaccord Genuity Wealth Ltd. 9.685 %	4,683,071	9.685 %	479 172 p
Amati Global Investors Ltd. (Venture Capital) 9.612 %	4,647,697	9.612 %	475 552 p
CFE (UK) Ltd. 7.978 %	3,857,566	7.978 %	394 706 p
Hargreaves Lansdown Asset Management Ltd. 3.632 %	1,756,000	3.632 %	179 674 p
City Asset Management Plc 2.953 %	1,427,860	2.953 %	146 099 p
Hardsteel Ltd. 1.752 %	847,000	1.752 %	86 665 p
Marcus Sarner 1.295 %	626,000	1.295 %	64 052 p

Ixico Plc

Griffin Court 15 Long Lane

EC1A 9PN, London

+44 20 3763 7499

http://www.ixico.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
IXICO PLC	-35.00%	4.93M
MODERNA, INC.	+25.69%	47.86B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.66B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
BIO-TECHNE CORPORATION	+0.17%	12.15B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research